Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma

PURPOSE: Over the past 30 years, no consistent survival benefits have been recorded for anticancer agents of advanced hepatocellular carcinoma (HCC), except for the multikinase inhibitor sorafenib (Nexavar(®)), which clinically achieves only ~3 months overall survival benefit. This modest benefit is...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Mahmoud MA, Mostafa, Mahmoud E, Alaaeldin, Eman, Sarhan, Hatem AA, Shaykoon, Montaser ShA, Allam, Shady, Ahmed, Ahmed RH, Elsadek, Bakheet EM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825507/
https://www.ncbi.nlm.nih.gov/pubmed/31754301
http://dx.doi.org/10.2147/IJN.S223920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825507/
https://www.ncbi.nlm.nih.gov/pubmed/31754301
http://dx.doi.org/10.2147/IJN.S223920

Ejemplares similares